Quick Answer
Phathom Pharmaceuticals, Inc. reported Research And Development Expense of $32.78 million for the year ending 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -3.8% in Research And Development Expense from 2024 to 2025.
- This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $6.0 thousand | Q4 2018: $14.0 thousand | Q1 2019: $429.0 thousand | Q2 2019: $2.77 million | Q3 2019: $4.47 million | Q4 2019: $12.70 million | Q1 2020: $15.87 million | Q2 2020: $14.86 million | Q3 2020: $25.77 million | Q4 2020: $41.65 million | Q1 2021: $20.58 million | Q2 2021: $21.60 million | Q3 2021: $16.61 million | Q1 2022: $17.66 million | Q2 2022: $18.82 million | Q3 2022: $19.02 million | Q1 2023: $11.48 million | Q2 2023: $12.76 million | Q3 2023: $12.26 million | Q1 2024: $9.43 million | Q2 2024: $7.38 million | Q3 2024: $8.69 million | Q1 2025: $9.18 million | Q2 2025: $9.08 million | Q3 2025: $7.03 million.
- Over the full 8 years of available data (2018 to 2025), Phathom Pharmaceuticals, Inc.'s Research And Development Expense has grown by 163,800.0%.
- Historical annual values: Fiscal year 2025: $32.78 million | Fiscal year 2024: $34.08 million | Fiscal year 2023: $49.90 million | Fiscal year 2022: $71.44 million | Fiscal year 2021: $72.34 million | Fiscal year 2020: $98.15 million | Fiscal year 2019: $20.37 million | Fiscal year 2018: $20.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: